Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.
—
Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.
—
Daily adjusted close
Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.